NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,802.80+₹41.80 (+2.37%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.96% below the high.
Loading market information…
NSE · NATCOPHARM.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
NATCO Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 36.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
NATCO Pharma Limited’s forward annual dividend is ₹2.98 per share, paid semi-annual. The forward yield is 0.38% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
NATCO Pharma Limited’s next earnings report is currently expected on Nov 17, 2026, with estimated earnings per share of ₹9.04. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow NATCO Pharma Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | May 28, 2025 | ₹23.00+112.96% vs estimate | ₹12.21B-5.41% vs estimate |
|---|
| Q3 2025 | Feb 12, 2025 | ₹7.40-61.86% vs estimate | ₹4.75B-45.88% vs estimate |
|---|
| Q2 2025 | Nov 12, 2024 | ₹37.81+20.03% vs estimate | ₹13.71B+4.1% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,802.80+₹41.80 (+2.37%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.96% below the high.
₹4,626.40+₹46.40 (+1.01%)
Torrent Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 11.82% below the high.
₹1,355.30+₹10.30 (+0.77%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.18% below the high.
₹1,679.00+₹19.10 (+1.15%)
Aurobindo Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 3.56% below the high.
₹1,929.00+₹2.80 (+0.15%)
Ipca Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 5.35% below the high.
₹3,535.00+₹75.30 (+2.18%)
Ajanta Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 6.88% below the high.
₹841.50+₹4.15 (+0.5%)
Granules India Limited’s quoted price sits in the upper half of its reported 52-week range, 8.83% below the high.
₹798.20+₹3.35 (+0.42%)
Alembic Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 20.1% below the high.
